|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical examination included MDS-Unified Parkinson Disease Rating Scale part III, Mini Mental State Examination, and Montreal Cognitive Assessment.
|
31725927 |
2020 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accuracy of MDS-UPDRS section IV for detecting motor fluctuations in Parkinson's disease.
|
30737581 |
2019 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
While levodopa dose (SMD = 0.05, 95% CI: -0.09 -0.19,P = 0.48), Hoehn and Yahr stage(H & Y stage) (SMD =-0.05, 95% CI: -0.14 - 0.04,P = 0.27), MDS-UPDRS Part III score(UPDRS III score) (SMD =-0.05, 95% CI: -0.13 - 0.03,P = 0.24), PD duration (SMD =-0.23, 95% CI: 0.10 - 0.37,P < 0.01)and Mini-Mental Status Examination score (MMSE score) (SMD = 0.10, 95% CI: -0.11 - 0.31,P = 0.33)were not related with PD-ICDs+.
|
31167116 |
2019 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
|
31073716 |
2019 |
|
PAFAH1B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
People with Parkinson's disease underwent a battery of clinical assessments to evaluate symptom severity, including motor (MDS-UPDRS) and cognitive (ACE-R) assessments.
|
31275543 |
2019 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study evidenced that 12 weeks of probiotic consumption by individuals with PD had useful impacts on MDS-UPDRS and few metabolic profiles.
|
29891223 |
2019 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to this scale, the following measures were applied: MDS-Unified Parkinson's Disease Rating Scale, Mini-Mental State Examination, Frontal Assessment Behavior, and Ardouin Scale of Behavior in Parkinson's Disease (ASBPD).
|
30862454 |
2019 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, medical specialists refer to the MDS-UPDRS (Movement Disorder Society - sponsored revision of Unified Parkinson's Disease Rating Scale) that is the most widely used clinical scale for PD rating.
|
31830986 |
2019 |
|
PAFAH1B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Baseline clinical, CSF, and imaging measures in early PD predicted change in MDS-UPDRS and dopamine-transporter binding, but the predictive value of the models was low.
|
31450510 |
2019 |
|
PAFAH1B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present a 48-year-old woman with Parkinson's disease in whom carbidopa was added to Mucuna pruriens, resulting in marked motor improvement (documented on video and using MDS-UPDRS motor scores).
|
30856121 |
2019 |
|
PAFAH1B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data were obtained from the Parkinson's Progression Markers Initiative cohort and included repeated MDS-UPDRS measurements from 423 de novo Parkinson's disease patients (median follow-up: 54 months).
|
31291488 |
2019 |
|
PAFAH1B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the relationship between conventional measures of disease and motor severity (e.g., MDS-UPDRS part III), laboratory-based measures of gait and balance, and daily-living physical activity measures in patients with PD.
|
30718220 |
2019 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this work, a fuzzy inference model to evaluate hands pronation/supination exercises during the MDS-UPDRS motor examination is proposed to analyze different extracted features from the bio-mechanical signals acquired from patients with Parkinson's disease (PD) in different stages of severity.
|
29042162 |
2018 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The total MDS-UPDRS for PD was 32.4 compared to 4.6 for HC and 28.2 for SWEDD.
|
30564614 |
2018 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present 5-year longitudinal data on the change of the MDS-UPDRS and other clinical and dopamine transporter imaging outcome measures in early PD.
|
29572948 |
2018 |
|
PAFAH1B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AChE: acetylcholinesterase; AD: Alzheimer disease; DLB: dementia with Lewy bodies; ET: essential tremor; MDS-UPDRS: Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale; MMSE: Mini-Mental State Examination; PD: Parkinson disease; PDD: Parkinson disease dementia.
|
28911255 |
2018 |
|
PAFAH1B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, PD-Monitor scores in 97 PD patients with MDS-UPDRS FT bradykinesia and each PD subgroup (FT bradykinesia scored from 1 to 3) were all higher than that in NC.
|
30147869 |
2018 |
|
PAFAH1B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The striatal binding ratio was associated with PD risk estimates (P = .040), University of Pennsylvania Smell Identification Test (P = .002), Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire scores (P = .024), tapping speed (P = .024), and MDS-UPDRS motor scores (P = .009).
|
29380907 |
2018 |
|
PAFAH1B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correlations of clinical variables (i.e., PDQ-39 quality of life and MDS-UPDRS) with ALFF values were examined for the exercise-trained PD participants.
|
29273705 |
2017 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changes in MDS-UPDRS and UDysRS confirm that LCIG treatment can efficiently improve experiences of daily living in advanced PD.
|
28185758 |
2017 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study presents a framework for analyzing MDS-UPDRS data, which can be adapted to more traditional UPDRS data collected in PD clinical trials and result in more efficient designs and analyses of such studies.
|
28247193 |
2017 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extended-TUG time was significantly correlated to MDS-UPDRS III score and to SCOPA-Cog, ACE-R (p<0.001) and PDQ-39 scores (p<0.01).
|
28320196 |
2017 |
|
PAFAH1B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association of RBD, autonomic symptoms, and MDS-UPDRS Part II scores with psychosis underscore its link to brainstem dysfunction and greater PD motor symptom severity.
|
28735797 |
2017 |